CLINICAL TRIALS PROFILE FOR PRIMIDONE
✉ Email this page to a colleague
All Clinical Trials for PRIMIDONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006025 ↗ | Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | 2001-01-05 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. |
| NCT00006025 ↗ | Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma | Completed | North American Brain Tumor Consortium | Phase 1 | 2001-01-05 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. |
| NCT00006025 ↗ | Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | 2001-01-05 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma. |
| NCT00006773 ↗ | Bortezomib in Treating Patients With Recurrent Glioma | Terminated | National Cancer Institute (NCI) | Phase 1 | 2001-05-01 | Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| NCT00068770 ↗ | Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | Terminated | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2003-10-01 | RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PRIMIDONE
Condition Name
Clinical Trial Locations for PRIMIDONE
Trials by Country
Clinical Trial Progress for PRIMIDONE
Clinical Trial Phase
Clinical Trial Sponsors for PRIMIDONE
Sponsor Name
| Sponsor Name for PRIMIDONE | |
| Sponsor | Trials |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 6 |
| National Cancer Institute (NCI) | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
